CHMP has advised that Alhemo be approved for people with severe hemophilia A and moderate or severe hemophilia B without inhibitors.

In July 2025, CSL Behring conducted a study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after ...